【摘要】 目的：研究司美格鲁肽治疗2型糖尿病合并冠心病患者的临床疗效。方法：选取2021年5月到2022年12月我院纳入的84例2型糖尿病合并冠心病患者，随机分为对照组和试验组，对照组行常规胰岛素治疗，试验组加以司美格鲁肽治疗，比较两组患者血糖、血脂及炎症因子水平、心肌缺血总负荷及不良反应发生率。结果：经治疗后，试验组患者HbA1c、FBG、TG、LDL-C及IL-1β [(5.51±1.23)%,(6.12±1.08)mmol/L,(1.31±0.1)mmol/L,(2.74±0.16)mmol/L,(26.54±5.31)pg/m L]较对照组显著降低[(6.83±1.48)%,(6.84±1.3)mmol/L,(1.37±0.10)mmol/L,(2.97±0.20)mmol/L,(35.15±6.17)pg/m L],HDL-C及IL-10 [(1.17±0.12)mmol/L,(35.01±8.84)pg/ml]较对照组[(1.01±0.08)mmol/L,(25.54±4.62)pg/m L]显著升高；心肌缺血总负荷（293.64±11.58）nm·min较对照组（124.39±9.69）nm·min显著降低，以上数据比较差异均有统计学意义（P<0.05）。两组患者不良反应发生率差异无统计学意义（P>0.05）。结论：司美格鲁肽在对2型糖尿病合并冠心病患者的治疗中能够显著改善血糖、血脂水平，对心血管功能起到保护作用，且不良反应发生率低，值得在临床上进一步推广。更多还原

【Abstract】 Objective:To study the clinical efficacy of smeglutide in the treatment of patients with type 2diabetes mellitus complicated with coronary heart disease.Methods:84 patients with type 2 diabetes mellitus complicated with coronary heart disease admitted to our hospital from May 2021 to December 2022 were randomly divided into control group and experimental group.The control group was treated with conventional insulin treatment,and the experimental group was treated with semeglutide on the basic of conventional insulin treatment.The levels of blood glucose, blood lipid,inflammatory factors,total load of myocardial ischemia and the incidence of adverse reactions were compared between the two groups.Results:After treatment,HbA1c,FBG,TG,LDL-C and IL-1β [(5.51±1.23)%,(6.12±1.08)mmol/L,(1.31±0.1)mmol/L,(2.74±0.16)mmol/L,(26.54±5.31)pg/m L] in the experimental group were significantly lower than those in the control group [(6.83±1.48)%,(6.84±1.3)mmol/L,(1.37±0.10)mmol/L,(2.97 ±0.20)mmol/L,(35.15 ±6.17)pg/m L].HDL-C and IL-10 [(1.17 ±0.12)mmol/L,(35.01 ±8.84)pg/ml] were significantly higher than the control group [(1.01±0.08)mmol/L,(25.54±4.62)pg/ml]; The total load of myocardial ischemia(293.64±11.58)nm·min was significantly lower than that of the control group(124.39±9.69)nm·min.The above differences were statistically significant(P <0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Semeglutide can significantly improve blood glucose and blood lipid levels in the treatment of patients with type 2 diabetes mellitus and coronary heart disease. It can protect cardiovascular function and has a low incidence of adverse reactions.It is worthy of further promotion in clinical practice.更多还原